ssgj-706
mAbexperimentalBi-specific
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 31, 2024 (NCT06533605)
Timeline
Indications
Mechanism of action
- Programmed cell death 1 ligand 1INHIBITOR
CD274 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07233850 | Phase 2 | Nov 30, 2025 | Sunshine Lake Pharma Co., Ltd. |
| NCT07171606 | Phase 2 | Sep 30, 2025 | Sunshine Lake Pharma Co., Ltd. |
| NCT06533605 | Phase 1 | Aug 31, 2024 | Sunshine Lake Pharma Co., Ltd. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sunshine Lake Pharma Co., Ltd. | For profit | 3 | 3 | 2 | 2024 |
1 organizations
Page 1 / 1